Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinoma 2026-07-14T15:51:46-07:00July 8th, 2026|2026 Publications, Featured Publications, Publications| Read more
ELN-DAVID Recommendations for NGS-based FLT3-ITD MRD Testing in Patients with Acute Myeloid Leukemia 2026-07-09T17:06:05-07:00June 3rd, 2026|2026 Publications, Featured Publications, Publications| Read more
NGS-based MRD monitoring in mature B-cell and plasma cell malignancies 2026-07-09T17:08:21-07:00May 28th, 2026|2026 Publications, Featured Publications, Publications| Read more
T-cell receptor gamma (TRG) diversity predicts peripheral blood involvement in primary cutaneous T-cell lymphoma 2026-07-09T17:12:44-07:00March 5th, 2026|2026 Publications, Featured Publications, Publications| Read more
Ultrasensitive next-generation sequencing-based clonality assay for disease monitoring in B-cell acute lymphoblastic leukaemia 2026-07-07T11:50:22-07:00February 20th, 2026|2026 Publications, Featured Publications, Publications| Read more
Measurable Residual Disease detection in acute lymphoblastic leukaemia – comparison between targeted NGS and ASO-qPCR 2026-07-09T17:00:41-07:00January 23rd, 2026|2026 Publications, Featured Publications, Publications| Read more
Measurable residual disease monitoring after hematopoietic stem cell transplantation 2026-07-06T16:26:02-07:00December 30th, 2025|2025 Publications, Featured Publications, Publications| Read more
Measurable residual mutated NPM1 before allogeneic transplant for acute myeloid leukemia 2025-11-24T09:51:38-08:00November 24th, 2025|2025 Publications, Featured Publications, Publications| Read more
QuANTUM-First: Clinical Validation of the LeukoStrat Companion Diagnostic for the Selection of Patients With Acute Myeloid Leukemia Harboring FMS-Like Tyrosine Kinase 3–Internal Tandem Duplications for Treatment With Quizartinib 2026-04-20T09:03:35-07:00September 3rd, 2025|2025 Publications, Featured Publications, Publications| Read more
A Systematic, Evidence-Based Workflow for Classifying KMT2A Fusions in AML 2026-04-20T09:01:54-07:00July 29th, 2025|2025 Publications, Featured Publications, Publications| Read more
Performance Comparison of Illumina® MiSeq™ and MiSeq™ i100 Systems using Invivoscribe’s LymphoTrack® Assays 2026-04-20T09:00:11-07:00May 27th, 2025|2025 Publications, Featured Publications, Publications| Read more
From prognostication to precision in acute myeloid leukemia 2025-05-08T16:47:49-07:00May 8th, 2025|2025 Publications, Featured Publications, Publications| Read more
Measurable residual disease and post-transplantation gilteritinib maintenance for patients with FLT3 ITD mutated AML 2025-05-09T09:20:30-07:00May 8th, 2025|2025 Publications, Featured Publications, Publications| Read more
Comparison of Complete Genomics DNBSEQ-G99 Sequencer and Illumina® MiSeqTM using Invivoscribe’s FLT3 ITD MRD Assay and NPM1 MRD Assay 2026-01-07T13:13:14-08:00November 8th, 2024|2024 Publications, Featured Publications, Publications| Read more
Performance Comparison of Invivoscribe’s LymphoTrack® Assays Between Complete Genomics DNBSEQ-G99 and Illumina® MiSeqTM NGS Platforms 2026-04-20T09:02:18-07:00November 8th, 2024|2024 Publications, Featured Publications, Publications| Read more
Clonality and Measurable Residual Disease (MRD) Testing on the Illumina NextSeq Sequencers 2026-04-20T09:08:04-07:00June 21st, 2024|2024 Publications, Featured Publications, Publications| Read more
Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia 2026-04-20T09:04:28-07:00May 2nd, 2024|2024 Publications, Featured Publications, Publications| Read more
Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing 2024-03-26T13:55:01-07:00March 20th, 2024|2024 Publications, Featured Publications, Publications| Read more
Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal residual disease detection in Chinese patients with multiple myeloma 2026-04-20T09:07:34-07:00March 19th, 2024|2024 Publications, Featured Publications, Publications| Read more
Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing–Based Clonality Testing in B-Cell and Plasma Cell Neoplasms 2026-04-20T09:06:43-07:00March 1st, 2024|2024 Publications, Featured Publications, Publications| Read more
Leveraging Standardized MRD Assays to Guide CLL Treatment 2024-01-25T10:44:11-08:00January 25th, 2024|2024 Publications, Featured Publications, Publications| Read more
Clonal Characterization and Somatic Hypermutation Assessment by Next-Generation Sequencing in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 2023-04-10T20:22:16-07:00March 23rd, 2023|2023 Publications, Featured Publications, Publications| Read more
DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant 2024-08-02T14:22:45-07:00March 7th, 2023|2023 Publications, Featured Publications, Publications| Read more
Minimal/Measurable Residual Disease (MRD) Monitoring in Patients with Lymphoid Neoplasms by High-Throughput Sequencing of the T-Cell Receptor 2023-04-10T20:24:04-07:00March 2nd, 2023|2023 Publications, Featured Publications, Publications| Read more
Comparing Data Generated Using Multiparametric Flow Cytometry, Capillary Electrophoresis, and Next-Generation Sequencing in a Cohort of B-Cell Lymphoproliferative Disorder Samples 2022-12-29T21:22:21-08:00November 15th, 2022|2022 Publications, Featured Publications, Publications| Read more
